Location History:
- Moscow 117234, RU (2002 - 2005)
- Moscow, RU (2010 - 2019)
Company Filing History:
16 out of 17 
3 out of 35 
2 out of 832,718 Years Active: 2002-2019
Title: Innovations and Contributions of Maxim Vladimirovich Skulachev
Introduction: Maxim Vladimirovich Skulachev is a distinguished inventor based in Moscow, Russia, known for his significant contributions to the field of pharmaceutical sciences. With a remarkable portfolio of 21 patents, he has dedicated his career to developing advanced solutions for medical and veterinary ophthalmology, with a particular focus on neuroprotection.
Latest Patents: Among his latest innovations are two notable patents. The first patent addresses a pharmaceutical composition for use in medical and veterinary ophthalmology. This invention relates to the manufacturing and application of ophthalmic preparations that incorporate a mitochondria-addressed antioxidant along with auxiliary substances to effectively treat ophthalmological diseases in both humans and animals. The second patent focuses on the development of mitochondria-targeted antioxidants for treating age-related brain disorders. This method provides a neuroprotective effect against brain pathologies associated with reactive oxygen species originating from mitochondria (mROS). The SkQ mitochondria-targeted antioxidant can be administered to mammals either prophylactically or as a treatment for various brain pathologies, including brain trauma and stroke.
Career Highlights: Maxim's career has been marked by his work with innovative companies in the pharmaceutical sector. Notable among these is Mitotech SA, where he contributed to the development of mitochondria-targeted therapies. He also worked with Icon Genetics GmbH, further expanding his expertise in biopharmaceuticals. His deep understanding of both scientific and practical applications has led him to become a prominent figure in his area of specialization.
Collaborations: Throughout his career, Maxim has collaborated with several esteemed professionals, including Vladimir Petrovich Skulachev and Maxim Viktorovich Egorov. These collaborations have enhanced his research and development efforts, allowing for the shared exchange of ideas and expertise within the field.
Conclusion: Maxim Vladimirovich Skulachev exemplifies the spirit of innovation through his dynamic contributions to pharmaceutical science. His dedication to developing methods for improving health outcomes paves the way for future advancements in medicine. The impact of his patents is likely to benefit both human and veterinary medicine, solidifying his legacy as a key inventor in this vital field.